1. Home
  2. CNTY vs GRDX Comparison

CNTY vs GRDX Comparison

Compare CNTY & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Casinos Inc.

CNTY

Century Casinos Inc.

HOLD

Current Price

$1.27

Market Cap

40.8M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.50

Market Cap

39.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTY
GRDX
Founded
1992
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.8M
39.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CNTY
GRDX
Price
$1.27
$4.50
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
64.5K
80.8K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
51.31
N/A
EPS
N/A
N/A
Revenue
$430,529,000.00
N/A
Revenue This Year
$7.17
N/A
Revenue Next Year
$3.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.82
N/A
52 Week Low
$1.23
$1.87
52 Week High
$2.85
$6.93

Technical Indicators

Market Signals
Indicator
CNTY
GRDX
Relative Strength Index (RSI) 40.22 43.85
Support Level $1.24 $2.16
Resistance Level $1.47 $5.30
Average True Range (ATR) 0.06 0.59
MACD -0.01 -0.16
Stochastic Oscillator 14.02 4.12

Price Performance

Historical Comparison
CNTY
GRDX

About CNTY Century Casinos Inc.

Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: